loader
Please Wait
Applying Filters...

Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Taselisib, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Taselisib

    DIGITAL CONTENT

    PharmaCompass

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    2D Structure
    1. Also known as: Gdc-0032, 1282512-48-4, 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide, Gdc 0032, Taselisib [inn], Gdc0032
    Molecular Formula
    C24H28N8O2
    Molecular Weight
    460.5  g/mol
    InChI Key
    BEUQXVWXFDOSAQ-UHFFFAOYSA-N
    FDA UNII
    L08J2O299M
    Taselisib is an orally bioavailable inhibitor of the class I phosphatidylinositol 3-kinase (PI3K) alpha isoform (PIK3CA), with potential antineoplastic activity. Taselisib selectively inhibits PIK3CA and its mutant forms in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PIK3CA-expressing tumor cells. By specifically targeting class I PI3K alpha, this agent may be more efficacious and less toxic than pan PI3K inhibitors. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and causes increased tumor cell growth, survival, and resistance to both chemotherapy and radiotherapy. PIK3CA, which encodes the p110-alpha catalytic subunit of the class I PI3K, is mutated in a variety of cancer cell types and plays a key role in cancer cell growth and invasion.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide
    2.1.2 InChI
    InChI=1S/C24H28N8O2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14H,8-9H2,1-5H3,(H2,25,33)
    2.1.3 InChI Key
    BEUQXVWXFDOSAQ-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC1=NN(C(=N1)C2=CN3CCOC4=C(C3=N2)C=CC(=C4)C5=CN(N=C5)C(C)(C)C(=O)N)C(C)C
    2.2 Other Identifiers
    2.2.1 UNII
    L08J2O299M
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 2-(3-(2-(1-isopropyl-3-methyl-1h-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide

    2. Gdc-0032

    3. Gdc0032

    4. Ro5537381

    2.3.2 Depositor-Supplied Synonyms

    1. Gdc-0032

    2. 1282512-48-4

    3. 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide

    4. Gdc 0032

    5. Taselisib [inn]

    6. Gdc0032

    7. Taselisib (gdc0032)

    8. Rg-7604

    9. Rg7604

    10. Chembl2387080

    11. L08j2o299m

    12. Rg 7604

    13. 2-methyl-2-(4-{2-[3-methyl-1-(propan-2-yl)-1h-1,2,4-triazol-5-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl}-1h-pyrazol-1-yl)propanamide

    14. Taselisib [usan:inn]

    15. Unii-l08j2o299m

    16. 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide

    17. Taselisibgdc-0032

    18. Taselisib (usan/inn)

    19. Taselisib [usan]

    20. Taselisib [who-dd]

    21. Taselisib (gdc-0032)

    22. Gtpl7794

    23. Schembl1485247

    24. Dtxsid00155842

    25. Hms3674g19

    26. Amy39941

    27. Bcp09253

    28. Ex-a1581

    29. Bdbm50434806

    30. Mfcd26142641

    31. Nsc777425

    32. Nsc800985

    33. S7103

    34. Zinc68267049

    35. Akos026750303

    36. Ccg-269338

    37. Cs-1817

    38. Db12108

    39. Gdc-0032, Taselisib; Rg-7604

    40. Nsc-777425

    41. Nsc-800985

    42. Sb16576

    43. Ncgc00387039-02

    44. 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide

    45. Ac-32794

    46. As-10662

    47. Bg166285

    48. Hy-13898

    49. D11774

    50. J-690119

    51. Q27088940

    52. 1395408-87-3

    53. 1h-pyrazole-1-acetamide, 4-(5,6-dihydro-2-(3-methyl-1-(1-methylethyl)-1h-1,2,4-triazol-5-yl)imidazo(1,2-d)(1,4)benzoxazepin-9-yl)-.alpha.,.alpha.-dimethyl-

    54. 1h-pyrazole-1-acetamide, 4-[5,6-dihydro-2-[3-methyl-1-(1-methylethyl)-1h-1,2,4-triazol-5-yl]imidazo[1,2-d][1,4]benzoxazepin-9-yl]-alpha,alpha-dimethyl-

    55. 3-({[(3r,5r)-3-butyl-3-ethyl-7-methoxy-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl]methyl}amino)pentanedioic Aci D

    56. 4-[5,6-dihydro-2-[3-methyl-1-(1-methylethyl)-1h-1,2,4-triazol-5-yl]imidazo[1,2-d][1,4]benzoxazepin-9-yl]-

    57. A,

    58. A-dimethyl-1h-pyrazole-1-acetamide

    2.4 Create Date
    2011-04-12
    3 Chemical and Physical Properties
    Molecular Weight 460.5 g/mol
    Molecular Formula C24H28N8O2
    XLogP31.8
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count5
    Exact Mass460.23352217 g/mol
    Monoisotopic Mass460.23352217 g/mol
    Topological Polar Surface Area119 Ų
    Heavy Atom Count34
    Formal Charge0
    Complexity751
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    Post Enquiry
    POST ENQUIRY